Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response

Objectives: Better markers of early response to neoadjuvant chemotherapy (NACT) in patients with breast cancer are required to enable the timely identification of non-responders and reduce unnecessary treatment side-effects. Early functional imaging may better predict response to treatment than conventional measures of tumour size. The purpose of this study was to test the hypothesis that the change in tumour blood flow after one cycle of NACT would predict pathological response. Methods: In this prospective cohort study, dynamic contrast-enhanced MRI was performed in 35 females with breast cancer before and after one cycle of epirubicin and cyclophosphamide-based NACT (EC90). Estimates of tumour blood flow and tumour volume were compared with pathological response obtained at surgery following completion of NACT. Results: Tumour blood flow at baseline (mean ± SD; 0.32 ± 0.17 ml/min/ml) reduced slightly after one cycle of NACT (0.28 ± 0.18 ml/min/ml). Following treatment 15 patients were identified as pathological responders and 20 as non-responders. There were no relationships found between tumour blood flow and pathological response. Conversely, tumour volume was found to be a good predictor of pathological response (smaller tumours did better) at both baseline (area under the receiver operating characteristic curve 0.80) and after one cycle of NACT (area under the receiver operating characteristic curve 0.81). Conclusion & advances in knowledge: The change in breast tumour blood flow following one cycle of EC90 did not predict pathological response. Tumour volume may be a better early marker of response with such agents.

[1]  C. Shi,et al.  The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis , 2020, Frontiers in Oncology.

[2]  Tomoharu Sugie,et al.  Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration , 2019, Histopathology.

[3]  D. Buckley,et al.  A functional form for a representative individual arterial input function measured from a population using high temporal resolution DCE MRI , 2018, Magnetic resonance in medicine.

[4]  Alexandre Cochet,et al.  Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response , 2018, The Journal of Nuclear Medicine.

[5]  D. Buckley,et al.  Estimating breast tumor blood flow during neoadjuvant chemotherapy using interleaved high temporal and high spatial resolution MRI , 2018, Magnetic resonance in medicine.

[6]  Bonnie N. Joe,et al.  Imaging Neoadjuvant Therapy Response in Breast Cancer. , 2017, Radiology.

[7]  Mitchell D Schnall,et al.  Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. , 2016, Radiology.

[8]  Thomas E Yankeelov,et al.  Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer , 2015, Investigative radiology.

[9]  Woo Kyung Moon,et al.  Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response , 2015 .

[10]  N Houssami,et al.  Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. , 2012, Breast.

[11]  J. Wildberger,et al.  Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review , 2012, European Radiology.

[12]  L. Esserman,et al.  Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.

[13]  T. Nagaoka,et al.  Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. , 2012, Radiology.

[14]  D L Buckley,et al.  Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability , 2012, Physics in medicine and biology.

[15]  J. Bonneterre,et al.  Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course , 2011, Breast Cancer Research and Treatment.

[16]  D. Mankoff,et al.  Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer , 2010, Clinical Cancer Research.

[17]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[18]  Julie R. Gralow,et al.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hon J. Yu,et al.  MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy , 2007, Journal of magnetic resonance imaging : JMRI.

[21]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[22]  Carmel Hayes,et al.  Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.

[23]  R. Lucht,et al.  Microcirculation and microvasculature in breast tumors: Pharmacokinetic analysis of dynamic MR image series , 2004, Magnetic resonance in medicine.

[24]  Robert B Livingston,et al.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  I. Zuna,et al.  Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.

[26]  F. Kelcz,et al.  Accurate and rapid quantitative dynamic contrast‐enhanced breast MR imaging using spoiled gradient‐recalled echoes and bookend T1 measurements , 1999, Magnetic resonance in medicine.